Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655169 | 0.86 | TSHR (0.33) | TSHR | |
| SCHEMBL16428382 | 0.84 | TSHR (0.42) | TSHR | |
| SCHEMBL2761440 | 0.82 | TSHR (0.40) | TSHR | |
| SCHEMBL56365 | 0.81 | — | — | |
| SCHEMBL56670 | 0.81 | — | — | |
| SCHEMBL28248627 | 0.78 | LMNA (0.50) | — | |
| SCHEMBL19534937 | 0.78 | LMNA (0.34) | TSHR | |
| SCHEMBL306582 | 0.78 | — | — | |
| SCHEMBL9273171 | 0.77 | TSHR (0.40) | TSHR | |
| SCHEMBL8081469 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912622-B | Tricyclic pyrimidinone compounds, methods of making, compositions and uses thereof | 上海纽思克生物科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-109384727-B | Phthalazinone compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-07-28 | — | — | CN | claimed |
| CN-113861220-B | Tricyclic pyrimidinone compounds, methods of making, compositions and uses thereof | 上海纽思克生物科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-115745987-A | Luciferase substrate and preparation method and application thereof | 华东理工大学 | 2023-03-07 | — | — | CN | claimed |
| CN-118344728-A | Molded article, method for producing molded article subjected to laser marking, and laser marking method | 旭化成株式会社 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024145346-A1 | CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONS | LYGG CORPORATION (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024137743-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| CN-118234717-A | Bicyclic heteroaromatic compounds and their use as pest control agents | PI工业有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024129948-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF S1P5 | CELGENE CORPORATION (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-118201895-A | Polymer-free and low-odor urease inhibitor formulations with improved storage stability on urea | 巴斯夫欧洲公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118159510-A | Urease inhibitor formulations for urea granulation | 巴斯夫欧洲公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20040127501-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2004-07-01 | — | — | US | disclosed |
| WO-2004029044-A1 | PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS | EURO-CELTIQUE, S.A. (LU) | 2004-04-08 | — | — | WO | disclosed |
| US-20040063681-A1 | Methods for using gold (III) complexes as anti-tumor and anti-HIV agents | CHE CHI-MING (CN) | 2004-04-01 | — | — | US | disclosed |
| WO-2004024146-A1 | METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053914-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| WO-2003093236-A1 | 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 2003-11-13 | — | — | WO | disclosed |
| EP-0353032-B1 | 1,5-BENZOTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Sankyo Company Limited (JP) | 1992-02-26 | — | — | EP | disclosed |
| EP-0353032-A1 | 1,5-benzothiazepine derivatives, their preparation and their use in the treatment of cardiovascular disorders | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053914-A1 | Therapeutic agents useful for treating pain | SMN1; SMN2, OPRM1, PSEN1 | TSHR 2139/4885 |
| US-20040063681-A1 | Methods for using gold (III) complexes as anti-tumor and anti-HIV agents | HCCS, ME3, IDH1 | TSHR 4228/4885 |
| US-20040127501-A1 | Therapeutic agents useful for treating pain | CACNA1A, GRIN2A, HTT | TSHR 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.